RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Sirnaomics, a US-China company developing RNAi therapeutics against cancer and fibrotic diseases, completed a $22 million C2 round from China investors, bringing the total C funding to $47 million. The C2 round was led by CR-CP Life Sciences Fund, a Hong Kong JV formed by China Resources and Charoen Pokphand Group, two Asian conglomerates. Sirnaomics will use the proceeds to support clinical trials of its RNAi candidates, while it advances its technology platforms. Sirnaomics is headquartered in Maryland with China operations in Suzhou and Guangzhou.
Source: China Biotoday
